Unlocking allogeneic cell therapy

A deep dive into current approaches to achieving durability

While autologous cell therapies have provided new options for cancer patients, the approach is logistically complex, expensive, and not scalable. Allogeneic approaches that enable cells from one donor to treat multiple patients offer a more extensible and economically viable way to harness the power of cell-based treatments. But durability remains challenging due to clearance of the transplanted cells by the host immune system, and the potential for inflammation.

In this webinar, Ruby Tsai, Ph.D., the Chief Scientific Officer of Applied StemCell provides an overview of how allogeneic cell therapy developers are overcoming challenges to durability. Starting with approved allogeneic cell therapies, then allogeneic treatments in clinical trials, and finally approaches not yet past IND, Dr. Tsai reviews which methods are working and how genome engineering and iPSCs are making scalable allogeneic cell therapies possible.